Pfizer’s Phase 3 BREAKWATER trial showed Braftovi combo improved response rates and duration in BRAF V600E-mutant metastatic colorectal cancer.
Pfizer’s Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer Patients
